This company listing is no longer active
Alimera Sciences (ASZ1) Stock Overview
A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
ASZ1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alimera Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.73 |
| 52 Week High | €5.09 |
| 52 Week Low | €2.43 |
| Beta | 0.27 |
| 1 Month Change | 0.85% |
| 3 Month Change | -6.44% |
| 1 Year Change | 68.75% |
| 3 Year Change | 27.02% |
| 5 Year Change | -23.26% |
| Change since IPO | -95.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASZ1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | -1.4% |
| 1Y | 68.8% | 18.3% | 10.0% |
Return vs Industry: ASZ1 exceeded the German Pharmaceuticals industry which returned -16.5% over the past year.
Return vs Market: ASZ1 exceeded the German Market which returned 6.8% over the past year.
Price Volatility
| ASZ1 volatility | |
|---|---|
| ASZ1 Average Weekly Movement | 24.6% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: ASZ1's share price has been volatile over the past 3 months.
Volatility Over Time: ASZ1's weekly volatility has increased from 13% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 157 | Rick Eiswirth | alimerasciences.com |
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).
Alimera Sciences, Inc. Fundamentals Summary
| ASZ1 fundamental statistics | |
|---|---|
| Market cap | €256.97m |
| Earnings (TTM) | -€13.68m |
| Revenue (TTM) | €89.29m |
Is ASZ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASZ1 income statement (TTM) | |
|---|---|
| Revenue | US$99.68m |
| Cost of Revenue | US$13.57m |
| Gross Profit | US$86.11m |
| Other Expenses | US$101.39m |
| Earnings | -US$15.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 86.39% |
| Net Profit Margin | -15.32% |
| Debt/Equity Ratio | 179.8% |
How did ASZ1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/23 09:12 |
| End of Day Share Price | 2024/09/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alimera Sciences, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Caroline Corner | Cantor Fitzgerald & Co. |